Seller record · Telehealth service

Belle

By Paul Harris, Standards EditorRecorded September 2026 · Standard v1.1 · How checks are performed

Fails 1 of 8 criteria. S5, analytical documentation: No certificate of analysis or lot document is published on the product pages, the pricing page, the terms or the privacy policy.

At a glance

BelleTelehealth service

7/8criteria passed

Price: Semaglutide from $109 a month, tirzepatide from $189
Sells: compounded semaglutide, compounded tirzepatide, and 8 more
FDA letters: 1 on file

Visit Belle See all eight dispositions

Telehealth service. Passes 7 of 8 criteria. Recorded against Standard v1.1.

A telehealth service selling compounded semaglutide and tirzepatide, a tirzepatide microdose, NAD+, sermorelin, glutathione and a GHK-Cu copper peptide cream, with supply-length prices on every product. Its terms name four dispensing pharmacies with their cities, and an FDA warning letter of February 2026 names the company.

Operating entity Belle Health LLC

Dispositions

Code	Criterion	Disposition	Where it appears
S1	Prescriber requirement	PASS	Belle's compounded semaglutide product page; Belle's terms
S2	Prescription gating	PASS	Belle's GLP-1 page on its apply storefront; Belle's compounded semaglutide product page
S3	Pharmacy identification	PASS	Belle's terms; Belle's FAQ; Belle's treatments page
S4	Compounding disclosure	PASS	Belle's compounded semaglutide product page; Belle's sermorelin product page
S5	Analytical documentation	FAIL	Belle's treatments page; Belle's terms
S6	Business address	PASS	Belle's terms; Belle's privacy page; Belle's contact page
S7	Price disclosure	PASS	Belle's treatments page; Belle's NAD+ plus product page; Belle's copper peptide cream product page
S8	Enforcement status	PASS	fda.gov; letter 721795

Evidence, criterion by criterion

The evidence behind each disposition in the table above, where it appears, and its date.

S1PASSA licensed clinician reviews each screening and decides whether treatment is right, and the terms name Belle Health, LLC as the telehealth provider group.Source: Belle's compounded semaglutide product page; Belle's terms.

S2PASSThe start button opens a qualification screen asking sex, height and weight, and medication ships only if a clinician approves the screening.Source: Belle's GLP-1 page on its apply storefront; Belle's compounded semaglutide product page.

S3PASSThe terms name four dispensing pharmacies: BPI Labs, Inc. in Largo, FL, VitalRx Pharmacy in Pearland, TX, The Pharmacy Hub in Miami, FL and Olympia Pharmaceuticals in Orlando, FL, and the FAQ repeats the four names. The pricing page lists a wider set of partners, among them Hallandale Pharmacy, ReviveRX and VialsRx, each with no state.Source: Belle's terms; Belle's FAQ; Belle's treatments page.

S4PASSEach product page states that the compounded drug is not FDA-approved, in an important notice on the same page as the price.Source: Belle's compounded semaglutide product page; Belle's sermorelin product page.

S5FAILNo certificate of analysis or lot document is published on the product pages, the pricing page, the terms or the privacy policy.Source: Belle's treatments page; Belle's terms.

S6PASSBelle Health LLC at 12244 S Business Park Dr, Draper, UT 84020, printed in the terms and the privacy policy. The contact page prints the same building as 12244 Business Park Dr Ste 230, Draper, UT 84020.Source: Belle's terms; Belle's privacy page; Belle's contact page.

S7PASSCompounded semaglutide at $199 for a 1-month supply, down to $109 a month on a 12-month supply, and compounded tirzepatide at $249 for a 1-month supply, down to $189 a month on a 12-month supply. NAD+ from $149 a month, sermorelin and glutathione from $119, the tirzepatide microdose from $99 and the GHK-Cu copper peptide cream from $199.Source: Belle's treatments page; Belle's NAD+ plus product page; Belle's copper peptide cream product page.

S8PASSFDA warning letter 721795, February 2026, names Belle Health LLC dba Belle and Belle's website, alleging that pictured labels presented Belle as the compounder of its semaglutide and tirzepatide when it is not. No FDA action has halted the business, and the seller still trades.Source: fda.gov; letter 721795.

Products shown on the seller's own pages at the recorded date: compounded semaglutide, compounded tirzepatide, compounded tirzepatide microdose, NAD+ injection, sermorelin, glutathione, GHK-Cu copper peptide cream, MIC+B12, brand-name GLP-1 medications, oral minoxidil.

Other sellers of the same products

Who sells semaglutide Who sells tirzepatide Who sells sermorelin Who sells NAD+Who sells glutathione Who sells GHK-Cu

Enforcement documents on file: 1 warning letter

FDA warning letter 721795, issued February 2026, to Belle Health LLC dba BellePictured labels identify Belle as the compounder of semaglutide and tirzepatide products when it is not, which the letter calls false or misleading.

A warning letter alleges violations and requests a response. It does not halt a business, and it does not remove a seller from this ledger. Every letter recorded here.

Unpaid link. Belle does not pay the site, and nothing is earned when it is used. Funding.

Visit Belle

Dispositions recorded against Standard v1.1. Method and null semantics: how checks are performed. This record is not a review and contains no medical advice.